Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KPTINASDAQ:NAMSNASDAQ:NGMNASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKPTIKaryopharm Therapeutics$4.55-0.9%$5.13$3.51▼$17.40$39.31M0.3382,104 shs99,040 shsNAMSNewAmsterdam Pharma$17.01-3.4%$18.32$14.06▼$27.29$1.87B0.01639,792 shs807,213 shsNGMNGM Biopharmaceuticals$1.54$1.55$0.60▼$4.69$128.53M1.271.47 million shsN/AXOMAXOMA$24.92+0.3%$22.67$18.35▼$35.00$298.22M0.8930,822 shs21,233 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKPTIKaryopharm Therapeutics-0.87%-11.82%-19.04%-53.71%-71.11%NAMSNewAmsterdam Pharma-3.41%-12.09%-2.91%-13.70%-9.62%NGMNGM Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%XOMAXOMA+0.28%-6.32%+3.23%+8.68%+0.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKPTIKaryopharm Therapeutics3.9502 of 5 stars3.50.00.04.63.62.50.6NAMSNewAmsterdam Pharma2.5779 of 5 stars3.51.00.00.02.85.00.0NGMNGM BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXOMAXOMA4.0922 of 5 stars3.52.00.03.03.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKPTIKaryopharm Therapeutics 3.00Buy$43.20849.45% UpsideNAMSNewAmsterdam Pharma 3.00Buy$43.00152.79% UpsideNGMNGM Biopharmaceuticals 0.00N/AN/AN/AXOMAXOMA 3.00Buy$69.50178.89% UpsideCurrent Analyst Ratings BreakdownLatest KPTI, NGM, NAMS, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025KPTIKaryopharm TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.005/13/2025KPTIKaryopharm TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.005/13/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.005/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $40.004/17/2025XOMAXOMABenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/28/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/19/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/3/2025NAMSNewAmsterdam PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$41.003/3/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$75.00 ➝ $54.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKPTIKaryopharm Therapeutics$142.13M0.28N/AN/A($1.47) per share-3.10NAMSNewAmsterdam Pharma$47.14M39.63N/AN/A$3.50 per share4.86NGMNGM Biopharmaceuticals$4.42M29.10N/AN/A$1.80 per share0.86XOMAXOMA$13.05M22.86N/AN/A$7.72 per share3.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKPTIKaryopharm Therapeutics-$143.10M-$13.26N/AN/AN/A-52.62%N/A-39.58%8/5/2025 (Estimated)NAMSNewAmsterdam Pharma-$176.94M-$1.88N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)NGMNGM Biopharmaceuticals-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/AXOMAXOMA-$40.83M-$1.15N/AN/AN/A-151.34%-24.95%-9.64%8/12/2025 (Estimated)Latest KPTI, NGM, NAMS, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025XOMAXOMA-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million5/12/2025Q1 2025KPTIKaryopharm Therapeutics-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million3/17/2025Q4 2024XOMAXOMA-$0.29-$0.46-$0.17-$0.46$8.75 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ANGMNGM BiopharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKPTIKaryopharm TherapeuticsN/A1.702.93NAMSNewAmsterdam PharmaN/A10.6110.61NGMNGM BiopharmaceuticalsN/A7.797.79XOMAXOMA1.287.527.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKPTIKaryopharm Therapeutics66.44%NAMSNewAmsterdam Pharma89.89%NGMNGM Biopharmaceuticals75.74%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipKPTIKaryopharm Therapeutics2.75%NAMSNewAmsterdam Pharma20.84%NGMNGM Biopharmaceuticals35.90%XOMAXOMA9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKPTIKaryopharm Therapeutics3808.64 million122.72 millionOptionableNAMSNewAmsterdam Pharma4109.82 million74.37 millionOptionableNGMNGM Biopharmaceuticals13883.46 million53.50 millionOptionableXOMAXOMA1011.97 million10.94 millionOptionableKPTI, NGM, NAMS, and XOMA HeadlinesRecent News About These CompaniesXOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 MillionMay 27 at 8:01 AM | globenewswire.comWoodline Partners LP Acquires 60,927 Shares of XOMA Co. (NASDAQ:XOMA)May 27 at 4:37 AM | marketbeat.comInsider Selling: XOMA Co. (NASDAQ:XOMA) CEO Sells 25,637 Shares of StockMay 22, 2025 | insidertrades.comBvf Partners L. P/Il Sells 392,723 Shares of XOMA Co. (NASDAQ:XOMA) StockMay 21, 2025 | insidertrades.comMajor Shareholder Sells Massive Chunk of Xoma Stock!May 20, 2025 | tipranks.comStonepine Capital Management LLC Reduces Stock Holdings in XOMA Co. (NASDAQ:XOMA)May 20, 2025 | marketbeat.comLeerink Partnrs Analysts Boost Earnings Estimates for XOMAMay 20, 2025 | marketbeat.comXOMA Royalty First Quarter 2025 Earnings: Beats ExpectationsMay 15, 2025 | finance.yahoo.comXOMA Royalty Reports Strong Q1 2025 ResultsMay 14, 2025 | tipranks.comXOMA Royalty: Q1 Earnings SnapshotMay 13, 2025 | sfgate.comXOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business AchievementsMay 13, 2025 | finance.yahoo.comXOMA Royalty (XOMA) Tops Q1 Earnings and Revenue EstimatesMay 13, 2025 | zacks.comXOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceMay 7, 2025 | globenewswire.comXOMA (XOMA) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comHigh Growth Tech Stocks In The US To Watch April 2025April 22, 2025 | uk.finance.yahoo.comBenchmark Initiates Coverage of XOMA Royalty Corporation - Preferred Stock (XOMAP) with Buy RecommendationApril 18, 2025 | msn.comXoma initiated with a Buy at BenchmarkApril 17, 2025 | markets.businessinsider.comXoma (XOMA) Receives Buy Rating from Benchmark with Promising Growth Forecast | XOMA Stock NewsApril 17, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline AssetsApril 14, 2025 | gurufocus.comXOMA (XOMA) Sells Kinnate Biopharma Pipeline Assets for Potential $270M | XOMA Stock NewsApril 14, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline Assets | XOMA Stock NewsApril 14, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPTI, NGM, NAMS, and XOMA Company DescriptionsKaryopharm Therapeutics NASDAQ:KPTI$4.55 -0.04 (-0.87%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$4.59 +0.04 (+0.88%) As of 05/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.NewAmsterdam Pharma NASDAQ:NAMS$17.01 -0.60 (-3.41%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$17.01 0.00 (0.00%) As of 05/27/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.NGM Biopharmaceuticals NASDAQ:NGMNGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.XOMA NASDAQ:XOMA$24.92 +0.07 (+0.28%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$24.95 +0.03 (+0.12%) As of 05/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.